Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Multiple Myeloma
Multiple Myeloma
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
BioCentury
Mon, 06/3/19 - 08:17 pm
ASCO 2019
Celgene
Multiple Myeloma
Five Prime Therapeutics
Iovance
Merck
Moderna Therapeutics
Eli Lilly
ICR
#ASCO19: Sanofi sets the stage for a late arrival of their multiple myeloma drug isatuximab — with J&J and Genmab laying in wait
Endpoints
Sun, 06/2/19 - 01:18 pm
Sanofi
Multiple Myeloma
isatuximab
ASCO 2019
Mass exodus of Amgen sales reps sparks legal battle with multiple myeloma rival Karyopharm
Fierce Pharma
Fri, 05/24/19 - 04:35 pm
Amgen
sales poaching
drug reps
Karyopharm Therapeutics
Multiple Myeloma
Selinexor
After years of delays, NICE backs Celgene’s Revlimid in first-line MM
Pharmaforum
Fri, 05/17/19 - 07:18 pm
Celgene
Revlimid
Multiple Myeloma
NICE
NHS
England
Celgene reports 'durable' responses to multiple myeloma CAR-T in early trial despite relapses
Fierce Biotech
Fri, 05/3/19 - 10:45 am
Celgene
Bluebird Bio
bb2121
cell therapy
CAR-T
Multiple Myeloma
Roche throws in the towel on Tecentriq bladder, myeloma trials
Fierce Pharma
Fri, 04/19/19 - 06:16 pm
Roche
Tecentriq
bladder cancer
Multiple Myeloma
clinical trials
GSK mulls filings for multiple myeloma drug
Pharmaforum
Fri, 03/22/19 - 10:06 am
GSK
GSK2857916
antibody-drug conjugate
Multiple Myeloma
AbbVie stock down 0.8% after FDA places hold on clinical trials of venetoclax as a treatment for multiple myeloma
Marketwatch
Tue, 03/19/19 - 10:36 am
AbbVie
venetoclax
Multiple Myeloma
FDA
clinical trials
Karyopharm gets bump as FDA extends review of selinexor
BioCentury
Fri, 03/15/19 - 10:42 am
Karyopharm
FDA
Selinexor
Multiple Myeloma
J&J Seeks Approval for Darzalex in Expanded Patient Group
Yahoo/Zacks.com
Fri, 03/15/19 - 09:16 am
JNJ
Darzalex
Multiple Myeloma
FDA
U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug
Yahoo/Reuters
Thu, 03/14/19 - 10:18 am
Celgene
Revlimid
patents
Multiple Myeloma
Alvogen
Karyopharm down as FDA reviewers cast doubt on selinexor's benefit
BioCentury
Sat, 02/23/19 - 04:35 pm
Karyopharm Therapeutics
FDA
Selinexor
Multiple Myeloma
Celgene's Revlimid defenses withstand another challenge
Biopharma Dive
Tue, 02/12/19 - 10:14 am
Celgene
Revlimid
Multiple Myeloma
Dr Reddy's
patents
AbbVie gains option to Teneobio BCMA program
BioCentury
Mon, 02/11/19 - 08:04 pm
AbbVie
Teneobio
TNB-383B
Multiple Myeloma
Gilead drops anti-BCMA CAR-T from Kite, takes $820M charge
Fierce Biotech
Tue, 02/5/19 - 11:50 am
Gilead Sciences
Multiple Myeloma
Kite Pharma
anti-BCMA
Sanofi's isatuximab meets survival endpoint for third-line multiple myeloma
BioCentury
Tue, 02/5/19 - 10:09 am
Sanofi
FDA
EMA
isatuximab
relapsed or refractory multiple myeloma
Multiple Myeloma
Genmab's blockbuster Darzalex surpasses $2B in sales
BioCentury
Tue, 01/8/19 - 11:40 pm
Genmab
Multiple Myeloma
Darzalex
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Xtalks
Mon, 12/10/18 - 07:07 pm
clinical trials
Multiple Myeloma
adaptive trial design
AbbVie
Celgene
Eli Lilly
Genentech
Janssen
Takeda
ASH: J&J's fast-growing Darzalex lines up for second front-line myeloma OK
Fierce Pharma
Tue, 12/4/18 - 11:33 am
JNJ
Darzalex
Multiple Myeloma
ASH 2018
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »